Brainomix Announces New Phase III INBUILD® Data Highlighting Potential of Quantitative CT to Predict Disease Progression and Assess Treatment Response in Progressive Pulmonary Fibrosis

A 474-patient Phase III INBUILD HRCT sub-study found Brainomix e-Lung quantitative CT measures were sensitive to nintedanib’s treatment effects at 24 and 52 weeks and were associated with FVC decline over 52 weeks in progressive pulmonary fibrosis. The AJRCCM-published analysis cross-validated Brainomix’s software against UCLA research algorithms, supporting quantitative CT as a potential biomarker for trial stratification and assessment of antifibrotic treatment response. The findings are clinically supportive for Brainomix’s AI imaging platform but do not represent an FDA-reviewed outcome or a near-term commercial catalyst.

Analysis

This is primarily a clinical-trial-enablement signal, not a near-term therapeutic revenue catalyst. If quantitative CT becomes an accepted enrichment or endpoint-adjacent tool, antifibrotic developers could reduce patient heterogeneity and detect drug effects with smaller or shorter studies; the economic prize is lower trial cost and a higher probability of distinguishing marginal efficacy. The limiting step is regulatory qualification: an association with FVC and treatment sensitivity does not establish that qCT can substitute for validated clinical endpoints, so commercial uptake will likely lag publication by 12-36 months.

The more investable second-order implication is pressure on smaller pulmonary-fibrosis developers whose pipelines depend on long, expensive FVC-based trials and have limited balance-sheet runway. Earlier readouts could favor well-capitalized sponsors able to embed imaging prospectively, while vendors with validated workflow integration gain switching-cost advantages over research-only algorithms. Brainomix is private and Boehringer Ingelheim is not directly investable, leaving no clean listed single-name expression; public imaging/AI names should not re-rate materially without evidence of contracted trial deployments, reimbursement, or regulator acceptance.

Contrarian view: the market may overestimate the speed with which a technically credible imaging biomarker changes drug-development economics. Central-read infrastructure, scanner standardization, longitudinal reproducibility and FDA/EMA endpoint discussions can negate much of the theoretical time savings. The key falsifier for the adoption thesis is whether future interstitial-lung-disease protocols formally designate qCT for enrollment stratification or a prespecified decision-making role, rather than retaining it as exploratory analysis.

Key Decisions for Investors

• No immediate directional trade: the data are supportive but non-regulatory and do not create a direct listed-equity earnings revision over the next 1-3 months.
• Monitor upcoming pulmonary-fibrosis trial protocols from Roche (RHHBY), Gilead (GILD) and Galapagos (GLPG) for prospective qCT stratification or endpoint use over 6-18 months; treat such adoption as a modest positive for trial execution rather than proof of clinical efficacy.
• For biotech shorts with near-term fibrosis readouts, assess whether qCT-enriched enrollment materially changes cross-trial comparability before relying on FVC expectations; a favorable imaging signal without FVC confirmation should not be assumed to support approval.
• Set an alert for FDA or EMA biomarker-qualification guidance, or disclosed commercial trial contracts for Brainomix: either would be the catalyst needed to revisit public-market beneficiaries among imaging workflow and clinical-research-service providers.